Key indicators: single-crystal X-ray study; T = 293 K; mean (C-C) = 0.004 Å; R factor = 0.036; wR factor = 0.104; data-to-parameter ratio = 15.8.
The title compound, C 17 H 12 BrClN 2 O, was synthesized by oxidation of [3-(4-bromophenyl)-1-(4-chlorobenzyl)-1Hpyrazol-5-yl]methanol under mild conditions. The pyrazole ring makes dihedral angles of 3.29 (9) and 74.91 (4) , respectively, with the bromophenyl and chlorophenyl rings.
Related literature
For applications of nitrogen-containing heterocyclic compounds in the agrochemical and pharmaceutical fields, see: Ge et al. (2007 Ge et al. ( , 2009 Ge et al. ( , 2011 . For the biological activity of some pyrazole derivatives belonging to this class of compounds, see: Xia et al. (2007) . For a related compound, see: Hao et al. (2012) . Data collection: SMART (Bruker, 2005) ; cell refinement: SAINT (Bruker, 2005) ; data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: XP in SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXL97.
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Comment
Synthesis of nitrogen-containing heterocyclic compounds has been a subject of great interest due to the wide application in agrochemical and pharmaceutical fields (Ge et al. , 2009 (Ge et al. , 2011 . Some pyrazole derivatives which belong to this category have been of interest for their biological activities . Considerable efforts have been devoted to the development of novel pyrazole compounds. The title compound (Fig. 1 ) is a new pyrazole derivative, which was synthesized in order to study and compare its biological properties with other related compounds . The title compound was screened for anticancer activities and found to be inactive. We report here the crystal structure of the title compound. The pyrazole ring makes dihedral angles of 3.29 (9) and 74.91 (4)°, respectively, with the bromophenyl and chlorophenyl rings. This conformation is close to that found in a related pyrazole derivative (Hao et al., 2012) .
Experimental
A mixture of (3-(4-bromophenyl)-1-(4-chlorobenzyl)-1H-pyrazol-5-yl)methanol (0.02 mol) and PCC (0.06 mol) in DMF (50 ml) was stirred for 3 h. After the starting material was consumed (monitored by TLC), the reaction mixture was poured into water (100 ml) and extracted with dichloromethane. The organic extracts were washed with water, dried, filtered and concentrated. The final product was isolated by column chromatography on silica gel (yield 72%). Crystals of the title compound suitable for X-ray diffraction were obtained by allowing a refluxed solution of the product in ethyl acetate (0.10 M) to cool slowly to room temperature (without temperature control) and allowing the solvent to evaporate for 3 days.
Refinement
All H atoms were placed in geometrically calculated positions and refined using a riding model with C-H = 0.97 Å (for the CH 2 group) and 0.93 Å (for aromatic CH); their isotropic displacement parameters were set to 1.2 times the equivalent displacement parameter of their parent atoms.
Computing details
Data collection: SMART (Bruker, 2005) ; cell refinement: SAINT (Bruker, 2005) ; data reduction: SAINT (Bruker, 2005) ; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: XP in SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXL97 (Sheldrick, 2008) . where P = (F o 2 + 2F c 2 )/3 (Δ/σ) max = 0.001 Δρ max = 0.50 e Å −3 Δρ min = −0.43 e Å −3 Extinction correction: SHELXL97 (Sheldrick, 2008) , Fc * =kFc[1+0.001xFc 2 λ 3 /sin (2θ) (3) O1-C1-C2 125.6 (3) C10-C9-H9 119.8
